The Tohoku Journal of Experimental Medicine
Online ISSN : 1349-3329
Print ISSN : 0040-8727
ISSN-L : 0040-8727
Reduction of Acetoxymethyl-Methylnitrosamine-Induced Large Bowel Cancer in Rats by Indomethacin
TOMIO NARISAWAPETER HERMANEKMICHAEL HABSDIETLICH SCHMÄHL
Author information
JOURNAL FREE ACCESS

1984 Volume 144 Issue 3 Pages 237-243

Details
Abstract

NARISAWA, T., HERMANEK, P., NABS, M. and SCHMÄHL, D. Reduction of Acetoxymethyl-Methylnitrosamine-Induced Large Bowel Cancer in Rats by Indomethacin. Tohoku J. exp. Med., 1984, 144 (3), 237-243 - The nonsteroid anti-inflammatory drug indomethacin, a potent prostaglandin synthesis inhibitor, may play a role in preventing chemically-induced large bowel cancer development in rats. 250male Sprague-Dawley rats were given weekly intrarectal doses of 2mg/kg body weight of acetoxymethyl-methylnitrosamine (AMMN) in the first 10 weeks of the experiment to induce large bowel tumors. Experimental groups received a 0.001% aqueous solution of indomethacin ad libitum as drinking water for different time intervals. At autopsy in week 21, the indomethacin treatment in the first and second 10-week periods, or only in the second 10-week period significantly reduced the number of large bowel tumors compared to non-treatment control groups, while the treatment in the first 10-week period alone did not affect the tumor development. It was observed at autopsy in week 31 that the 10-week cessation of treatment after the effective treatments permitted the growth of tumors, but the treatment in the first and second 10-week periods was effective enough to supperss tumor apperance compared to other groups. It can be concluded that indomethacin has an antiproliferative activity on large bowel carcinogenesis.

Content from these authors
© Tohoku University Medical Press
Previous article Next article
feedback
Top